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Insulin resistance is associated with 
altered amino acid metabolism 
and adipose tissue dysfunction in 
normoglycemic women
Petri Wiklund1,2, Xiaobo Zhang1, Satu Pekkala2, Reija Autio3, Lingjia Kong4, Yifan Yang1, 
Sirkka Keinänen-Kiukaanniemi5, Markku Alen5,6 & Sulin Cheng1,2
Insulin resistance is associated adiposity, but the mechanisms are not fully understood. In this study, 
we aimed to identify early metabolic alterations associated with insulin resistance in normoglycemic 
women with varying degree of adiposity. One-hundred and ten young and middle-aged women were 
divided into low and high IR groups based on their median HOMA-IR (0.9 ± 0.4 vs. 2.8 ± 1.2). Body 
composition was assessed using DXA, skeletal muscle and liver fat by proton magnetic resonance 
spectroscopy, serum metabolites by nuclear magnetic resonance spectroscopy and adipose tissue 
and skeletal muscle gene expression by microarrays. High HOMA-IR subjects had higher serum 
branched-chain amino acid concentrations (BCAA) (p < 0.05 for both). Gene expression analysis of 
subcutaneous adipose tissue revealed significant down-regulation of genes related to BCAA catabolism 
and mitochondrial energy metabolism and up-regulation of several inflammation-related pathways in 
high HOMA-IR subjects (p < 0.05 for all), but no differentially expressed genes in skeletal muscle were 
found. In conclusion, in normoglycemic women insulin resistance was associated with increased serum 
BCAA concentrations, down-regulation of mitochondrial energy metabolism and increased expression 
of inflammation-related genes in the adipose tissue.
One of the earliest detectable defects in the metabolic continuum leading to type 2 diabetes is insulin resistance1. 
Impaired glucose homeostasis is associated with obesity2, but the means by which excessive adiposity induces 
insulin resistance and glucose intolerance remain controversial. Indeed, only about a quarter of the variance of 
insulin resistance is explained by BMI in the general population3. Studies have shown that increased risk of heart 
disease is independent of central obesity in individuals with metabolic syndrome4, and lean individuals may be 
as insulin resistant as those with type 2 diabetes5. On the other hand, not all overweight and obese individuals 
develop insulin resistance or other metabolic disorders6, suggesting that the quantitative impact of obesity per se 
on insulin sensitivity may not be as large as previously thought7.
Obesity-associated increase in plasma free fatty acids and accumulation of ectopic lipids are linked with 
the onset of peripheral and hepatic insulin resistance8. Dysregulated amino acid metabolism is also associated 
with obesity-related impaired insulin sensitivity9 and increased risk for future diabetes10. We have recently used 
high-through put metabolite quantification to identify metabolic differences between sedentary obese individuals 
with and without metabolic syndrome. We found that branched-chain and aromatic amino acids were strongly 
associated with insulin resistance and other metabolic risk factors, independent of fat mass and waist circumfer-
ence11. This finding suggests that excess fat mass alone does not explain the associations of these amino acids with 
insulin resistance. Thus, the source of increased branched-chain and aromatic amino acids, and the mechanisms 
by which they might contribute to impaired insulin sensitivity remain incompletely understood.
Recent evidence suggests that obesity is associated with altered adipose tissue metabolism, which in 
turn affects systemic glucose homeostasis and induces insulin resistance in skeletal muscle12,13. There is little 
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knowledge on the alterations in systemic, adipose tissue and skeletal muscle metabolism in relation to insulin 
resistance in normoglycemic individuals with varying degree of adiposity. Therefore, we aimed to investigate the 
systemic metabolite and gene expression profiles of subcutaneous adipose tissue and skeletal muscle in (fasting) 
normoglycemic women but differing in insulin resistance.
Results
Clinical characteristics of the low and high HOMA-IR groups. The high HOMA-IR group had higher 
body weight and BMI than the low HOMA-IR group (p < 0.01 for both, Table 1). High HOMA-IR subjects also 
had higher percent body fat, total and visceral fat mass (p < 0.01 for both). No significant difference in hepatic or 
intra-muscular fat was found. Fasting glucose concentrations were within the normoglycemic range in the major-
ity of the subjects (92%). HOMA-IR indices were almost three times higher in individuals in the high HOMA-IR 
group than in those in the low HOMA-IR group. This difference was largely due to the significantly higher fasting 
insulin levels in the high HOMA-IR group (p < 0.001). Serum triglyceride and leptin concentrations were higher 
and physical activity and aerobic fitness was lower in the high HOMA-IR than low HOMA-IR group (p < 0.05 
for all), but no difference in adiponectin was found. Dietary intake did not differ between the groups, nor was 
there a significant difference in plasma free fatty acids. No group by generation interaction was found on any of 
the variables.
low HOMA-IR (n = 55) high HOMA-IR (n = 55)
p-value
Group by 
generationMean 95% CI Mean 95% CI
Anthropometry
 Age (years) 35.1 (35.9, 36.3) 36.0 (35.0, 36.9) 0.269 0.096
 Height (cm) 165.7 (163.9, 167.7) 166.1 (164.5, 167.6 ) 0.837 0.562
 Weight (kg) 61.3 (58.4, 64.1) 67.3 (65.1, 69.5) 0.001 0.604
 BMI (weight(kg)/height(m)2) 22.3 (21.4, 23.2) 24.4 (23.7, 25.1) 0.002 0.497
Body composition
 Percent body fat 29.5 (27.3, 31.6) 35.0 (32.9, 37.1) 0.001 0.209
 FFM (kg) 40.6 (39.3, 42.0) 40.7 (39.6, 41.8) 0.944 0.417
 FM (kg) 17.8 (15.5, 20.1) 23.7 (21.9, 25.5) 0.001 0.266
 VAT (kg) 0.5 (0.47, 0.62) 0.7 (0.59, 0.70) 0.044 0.164
 Liver fat (%) 2.5 (0.9, 4.1 ) 2.7 (1.5, 4.0) 0.787 0.577
 IMCL (%) 0.2 (0.16, 0.25) 0.2 (0.17, 0.23) 0.796 0.261
 EMCL (%) 0.2 (0.15, 0.31) 0.3 (0.27, 0.39) 0.068 0.925
Metabolic biomarkers
 fs-glucose (mmol/l) 5.2 (5.0, 5.4) 5.5 (5.3, 5.6) 0.042 0.982
 fs-insulin (μU/ml) 4.1 (3.0, 5.1) 9.9 (9.0, 10.8) < 0.001 0.110
 HOMA-IR 0.9 (0.6, 1.2) 2.4 (2.2, 2.7) < 0.001 0.112
Lipids
 FFA (mmol/l) 3.6 (3.0, 4.2) 4.0 (3.5, 4.5) 0.308 0.968
 Triglycerides (mmol/l) 0.9 (0.7, 1.0) 1.1 (1.0, 1.2) 0.013 0.250
 Adipokines
 Leptin (ng/ml) 14.6 (9.0, 20.2) 27.4 (23.1, 31.7) 0.001 0.490
 Adiponectin (μg/ml) 10.4 (18.2, 20.6) 10.1 (8.4, 11.8) 0.830 0.375
Diet
 Energy (kcal) 1840.0 (1690, 1990) 1780.0 (1650, 1900) 0.523 0.583
 Protein (E%) 17.7 (16.3, 18.8) 18.3 (17.3, 19.3) 0.324 0.545
 Fat (E%) 34.5 (31.4, 36.0) 32.3 (30.1, 34.0) 0.283 0.564
 Carbohydrates (E%) 47.8 (44.8, 49.5) 49.4 (46.4, 50.3) 0.414 0.868
Physical activity and fitness
 LTPA (hours/week) 4.5 (3.8, 5.2) 3.6 (3.0, 4.1) 0.049 0.466
 VO2max (ml/kg/min) 41.1 (36.8, 45.5) 35.1 (31.3, 38.9) 0.042 0.540
Table 1.  General characteristics in the low and high HOMA-IR groups (MIXED model estimated 
marginal means with 95% confidence intervals are given taking into account genetic similarity and 
shared environment (daughter and mother) and contrast estimates’ p-values were used to localize the 
significant differences between the two groups and group by generation interaction). FFM = fat-free mass; 
FM = fat mass; SAT = subcutaneous adipose tissue; VAT = visceral adipose tissue; IMCL = intra-myocellular 
lipids; EMCL = extra-myocellular lipids; HOMA-IR = homeostatic model assessment of insulin resistance; 
OGTT = oral glucose tolerance test; Matsuda index = insulin sensitivity index; FFA = free fatty acids; 
E% = percentage of total energy intake; LTPA = leisure-time physical activity; VO2max = maximum oxygen 
uptake.
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Serum metabolites. Serum metabolite profile analysis revealed many similarities but also significant dif-
ferences between the high and low HOMA-IR groups (Table 2). There were no significant differences in the fatty 
acid and phospholipid (Table 2) and lipoprotein subclass concentrations (Supplementary Table S1) between the 
groups. However, concentrations of branched-chain amino acids (BCAA = isoleucine, leucine and valine), aro-
matic amino acids (AAA = phenylalanine and tyrosine), glycerol and orosomucoid were significantly higher in 
the high HOMA-IR group than the low HOMA-IR group (p < 0.05 for all). Only phenylalanine showed group by 
generation interaction. The differences between the groups remained significant after adjusting for age, total or 
visceral fat mass, physical activity and aerobic fitness.
To confirm that the circulating metabolite levels were not confounded by difference in adiposity, we inves-







generationMean 95% CI Mean 95% CI
Low-molecular weight metabolites
 betahydroxybutyrate 0.049 (0.033, 0.066 0.061 (0.046, 0.077) 0.357 0.253
 acetate 0.039 (0.036, 0.042) 0.043 (0.040, 0.046) 0.081 0.785
 acetoacetate 0.038 (0.032, 0.044) 0.034 (0.029, 0.040) 0.961 0.793
 alanine 0.374 (0.353, 0.394) 0.399 (0.380, 0.418) 0.261 0.305
 citrate 0.098 (0.092, 0.104) 0.102 (0.096, 0.108) 0.406 0.923
 creatinine 0.049 (0.046, 0.053) 0.051 (0.048, 0.055) 0.197 0.311
 glutamine 0.511 (0.494, 0.529) 0.533 (0.517, 0.550) 0.685 0.174
 glycerol 0.056 (0.047, 0.064) 0.074 (0.066, 0.082) 0.003 0.134
 glycine 0.257 (0.239, 0.276) 0.276 (0.259, 0.292) 0.685 0.211
 orosomucoid 1.225 (1.168, 1.281) 1.344 (1.291, 1.397) 0.045 0.443
 histidine 0.050 (0.047, 0.053) 0.056 (0.053, 0.058) 0.362 0.329
 isoleucine 0.038 (0.035, 0.041) 0.043 (0.040, 0.046) 0.040 0.959
 leucine 0.061 (0.057, 0.064) 0.069 (0.066, 0.073) 0.005 0.813
 valine 0.154 (0.144, 0.163) 0.174 (0.165, 0.183) 0.014 0.351
 BCAAsum 0.253 (0.237, 0.268) 0.288 (0.273, 0.302) 0.009 0.666
 phenylalanine 0.061 (0.058, 0.064) 0.066 (0.063, 0.069) 0.035 0.045
 tyrosine 0.041 (0.037, 0.044) 0.047 (0.044, 0.050) 0.030 0.089
 pyruvate 0.068 (0.061, 0.075) 0.077 (0.070, 0.083) 0.064 0.915
 lactate 0.891 (0.799, 0.984) 0.967 (0.877, 1.057) 0.253 0.101
 urea 0.052 (0.045, 0.058) 0.049 (0.043, 0.055) 0.731 0.131
Lipid extract constituents
 esterified cholesterol 2.691 (2.528, 2.855) 2.831 (2.675, 2.987) 0.147 0.422
 free cholesterol 1.020 (0.952, 0.1087) 1.097 (1.032, 1.161) 0.127 0.386
 omega3 fatty acids 0.361 (0.316, 0.406) 0.369 (0.326, 0.411) 0.699 0.551
 omega6 fatty acids 2.789 (2.626, 2.952) 2.920 (2.824, 3.136) 0.328 0.683
 omega7and 9 fatty acids 4.918 (4.510, 5.325) 5.422 (5.032, 5.812) 0.253 0.446
 total fatty acids 8.068 (7.505, 8.630) 8.770 (8.233, 9.308) 0.259 0.699
 linoleic acid 2.303 (2.157, 2.449) 2.501 (2.362, 2.641) 0.328 0.738
 polyunsaturated fatty acids 1.647 (1.493, 1.801) 1.690 (1.543, 1.837) 0.792 0.747
 docosahexanoic acid 0.143 (0.122, 0.164) 0.145 (0.125, 0.165) 0.716 0.872
 monounsaturated fatty acids 2.183 (1.976, 2.389) 2.429 (2.232, 2.626) 0.253 0.370
 total phosphoglycerides 0.620 (0.567, 0.673) 0.671 (0.620, 0.721) 0.685 0.763
 phosphocholines 1.526 (1.413, 1.639) 1.622 (1.514, 1730) 0.685 0.700
 sphingomyelines 0.202 (0.187, 0.216) 0.207 (0.193, 0.220) 0.685 0.520
 omega3/total fatty acid ratio 4.453 (4.066, 4.840) 4.165 (3.795, 4.536) 0.458 0.173
 omega6/total fatty acid ratio 34.87 (33.80, 35.95) 34.40 (33.36, 35.42) 0.676 0.206
  omega7and9/total fatty acid 
ratio 60.67 (59.61, 61.73) 61.45 (60.43, 62.46) 0.458 0.076
 fatty acid length 17.92 (17.84, 18.00) 17.94 (17.87, 18.01) 0.857 0.264
Table 2.  Serum low-molecular weight metabolites and lipid extract constituents in the low and high 
HOMA-IR groups(MIXED model estimated marginal means with 95% confidence intervals are given 
taking into account genetic similarity and shared environment (daughter and mother) and contrast 
estimates’ p-values were used to localize the significant differences between the two groups and group by 
generation interaction). P-values are adjusted for multiple comparisons using Benjamin-Hochberg correction. 
All metabolites are in mmol/l.
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in normal weight individuals. We found that serum BCAAs and orosomucoid were significantly higher in the 
high HOMA-IR group than the low HOMA-IR group (p < 0.05 for all) (Supplementary Table S2). No difference 
between the groups in the other metabolites was found. Total serum BCAA correlated with fs insulin (r = 0.388), 
even after adjusting for age, percent fat mass and visceral adipose tissue. The concentration of plasma free fatty 
acids was not associated with fs insulin (r = 0.108), HOMA-IR (r = 0.168), fat mass (r = 0.093) or visceral adipose 
tissue (r = 0.153) (p > 0.05 for all).
Adipose tissue gene expression. To elucidate the metabolic pathways characterizing or contributing to 
insulin resistance, we studied global transcript profiles of adipose tissue and skeletal muscle. Microarray anal-
ysis revealed 1093 differentially expressed genes (688 up-regulated and 405 down-regulated) in the adipose 
tissue of the high HOMA-IR group (Supplementary Table S4). Kyoto Encyclopedia of Genes and Genomes 
(KEGG) enrichment analysis of the differentially expressed genes (p < 0.05) identified 9 down-regulated and 15 
up-regulated pathways.
The up-regulated pathways in the adipose tissue revealed increased activation of immune response involv-
ing both innate and adaptive immune systems (Table 3). Lysosome was the most up-regulated pathway 
(p = 5.6 × 10−13), with contributions by genes involving all aspects of lysosome biogenesis and function, includ-
ing structural genes (LAMP1, LAMP2 and LAPTM5), several lysosomal acid hydrolases and transport proteins of 
lipids and cholesterol (MCOLN1 and NPC2) as well as proteins required for lysosome acidification (ATP6V0D2 
and ATP6AP1). Several chemokines (e.g., CCL2, CCL3, CCL4 and CCL5), which are produced by innate immune 
cells, and also by pre-adipocytes and mature adipocytes14 were also present in the up-regulated pathways. 
Consistently, leukocyte trans-endothelial migration, Fc gamma R-mediated phagocytosis, toll-like receptor sign-
aling, and the complement system, (complement C1 [C1S, C1QA, C1QB, C1QC]) were up-regulated in the high 
HOMA-IR subjects. Up-regulation of the B cell receptor signaling pathway was also observed, providing further 
evidence for the involvement of the adaptive immune system and infiltration of inflammatory cells to the adipose 
tissue in insulin resistance.
The most down-regulated pathway in the adipose tissue was valine, leucine and isoleucine degradation 
(p = 1.1 × 10−7, Table 4). The genes that mapped to this pathway encode the cytosolic and mitochondrial com-
ponents of the pathway and included both genes common to the degradation of all BCAAs, namely isoleucine, 
leucine and valine (BCAT1, BCKDHB) and those specific for the degradation of leucine (MCC2, AUH), isoleucine 
(PCCA, PCCB) and valine (HIBADH, ALDH6A1). Further, we found that systemic insulin resistance was also 
associated with significant down-regulation of the genes encoding proteins that play important roles in cellular 
energy homeostasis. These included a master regulator of mitochondrial biogenesis and function, peroxisome 
proliferator-activated receptor-gamma coactivator-1α (PPARGC1A) and mitochondrial acetyl-coenzyme A car-
boxylase beta (ACACB), which is an important regulator of fatty acid oxidation and synthesis. Further, peroxi-
some proliferator-activated receptor alpha (PPARA), which promotes the uptake, utilization, and catabolism of 
fatty acids, was also down-regulated in the high HOMA-IR group. Accordingly, down-regulation of the fatty acid 
degradation pathway and tricarboxylic acid cycle (TCA cycle) was observed. Other down-regulated pathways 
involved aromatic amino acid (phenylalanine and tryptophan) and short-chain fatty acid (propanoate) metabo-
lism, and lysine biosynthesis.
To ensure our observations were not biased, we validated our results with two other independent experiments 
in obese insulin-resistant subjects by using gene expression omnibus (GEO) and the GSE2663715 and GSE2095016 
and data sets, respectively. The up-regulated inflammation-related genes in the adipose tissue were similar in our 
study than in the study of Soronen et al.15 and Hardy et al.16 (Fig. 1). In addition, the inflammation and energy 
metabolism-related pathways in the adipose tissue were similarly up- and down-regulated than in obese insulin 
resistant women in the study of Soronen et al.15.
We then assessed the associations between adipose tissue gene expressions and clinical traits in non-obese 
individuals. Characteristics of the study participants are presented in Supplementary Table S3. The mean centroid 
of the BCAA catabolism pathway in the adipose tissue was associated with insulin sensitivity (Matsuda index) 
and fs-insulin (p < 0.05 for all) (Fig. 2). These associations remained significant after adjusting for age and percent 
fat mass or visceral fat mass. The BCAA catabolism pathway correlated closely with mitochondrial respiration 
and biogenesis, i.e., with the TCA cycle and PPARGC1A (p < 0.001) (Fig. 3). Maximum oxygen uptake (VO2max) 
correlated with the BCAA catabolism (r = 0.543) and the TCA cycle (r = 0.522) (p < 0.05 for all). Inflammation 
pathways were coordinately up-regulated with insulin resistance and adipokines, e.g., the chemokine signaling 
pathway correlated with insulin sensitivity (Matsuda index) (r = − 0.807), fs-insulin (r = 0.858), fs-adiponectin 
(r = − 0.598) and leptin (r = 0.428) (p < 0.001 for all). The chemokine signaling pathway displayed significant 
associations with the TCA cycle and BCAA catabolism (r = − 0.812 and r = − 0.788, respectively, p < 0.001 for 
both).
Skeletal muscle gene expression and signaling protein phosphorylation. Unexpectedly, when 
the transcriptomic data of skeletal muscle were studied, no differentially expressed genes were found between 
the low and high HOMA-IR samples. However, since skeletal muscle is the primary site of insulin-stimulated 
glucose disposal, we studied whether there were differences in the phosphorylation levels of several proteins 
related to glucose uptake, insulin signaling and mitochondrial energy metabolism. No differences in the phos-
phorylation levels of insulin receptor β or its downstream target Akt were found (Supplementary Figure S1). The 
level of phosphorylated AS160, which promotes translocation of glucose transporters to the cell membrane, was 
also similar between the groups. In addition, no differences in the expression of mitochondrial respiratory chain 
complex subunits, namely ATP5A, UQCRC2, MTCO1, SDHB and NDUFF88 between the groups were found 
(Supplementary Figure S1).
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Discussion
In this study with young and middle-aged normoglycemic women, we found that insulin resistance was asso-
ciated with increased serum BCAA levels, independent of obesity. Consistent with this, we found a significant 
down-regulation of genes related to BCAA catabolism and mitochondrial energy metabolism, concurrently with 
increased expression of inflammation-related genes in the adipose tissue.
Plasma free fatty acids are commonly elevated in obese individuals due to increased adipose tissue lipolysis17. 
Elevated circulating free fatty acids may accumulate in other insulin-responsive tissues, such as skeletal muscle 
and liver (where they interfere with insulin signaling and cause insulin resistance)18. However, we found that in 
normoglycemic women with varying degree of adiposity, insulin resistance was not associated with increased 
plasma free fatty acids, but instead with increased serum amino acid concentrations. Our observation partly 
agrees with a recent study in normal weight subjects discordant for insulin sensitivity19, and a meta-analysis by 
Karpe et al.20. It is tempting, therefore, to suggest that the contribution of circulating free fatty acids to insulin 
resistance may be relatively small.
Increased serum BCAA concentrations have been associated with obesity-related insulin resistance in earlier 
studies21–23. Our results suggest that perturbations in systemic BCAA homeostasis are related to insulin resist-
ance rather than to obesity per se, since significant difference in these amino acids was observed between the 
high and low HOMA-IR groups also in normal weight individuals (Table S2). The average difference in total 
BCAA between low and high HOMA-IR groups was ~14% in whole study population and ~10% in normal 
weight individuals. Whether such difference is physiologically meaningful is not clear. However, Sunny et al.24 
recently demonstrated that insulin-stimulated increases (10–20%) in plasma BCAA correlated significantly with 
insulin resistance indices in humans. They concluded that such small but chronic increase in circulating BCAA 
with insulin resistance may be sufficient to disrupt signaling events in the mitochondria of the muscle and liver 
thereby contributing to mitochondrial dysfunction. However, our study cannot show temporal relationships, 
although our results are compatible with previous studies25,26, which have suggested that BCAAs associate with 
insulin resistance.
It is unclear why serum BCAA is elevated in obesity and insulin resistance. Differences in diet23, protein 
turnover (muscle loss)27 or liver fat (fatty liver disease) can affect circulating levels of amino acids. However, in 
our study no difference in diet (protein intake), fat-free mass or liver fat content was observed between the low 
and high HOMA-IR groups. The positive correlation of BCAA with insulin concentration in our study is line 
P-value Count Size Pathway name Gene Names
5.6 × 10−13 36 121 Lysosome
ACP5, AP1B1, ARSB, ATP6AP1, ATP6V0B, ATP6V0D2, CD68, 
CTSA, CTSB, CTSG, CTSH, CTSS, CTSZ, DNASE2B, FUCA1, GAA, 
GBA, GLA, GLB1, GM2A, GUSB, HEXB, LAMP1, LAPTM5, LGMN, 
MAN2B1, MCOLN1, NAGA, NPC2, PLA2G15, PPT1, PSAP, LAMP2, 
SLC11A2, SMPD1, TCIRG1
2.2 × 10−5 28 156 Phagosome
ACTB, ACTG1, ATP6AP1, ATP6V0B, ATP6V0D2, ATP6V1B2, C1R, 
CD14, CLEC7A, CORO1A, CTSS, CYBA, FCGR2A, FCGR2B, FCGR3A, 
ITGB2, ITGB5, LAMP1, MARCO, MSR1, NCF2, NCF4, SEC61A1, 
TCIRG1, TUBA1C, TUBB2A, TUBB2B, VAMP3
2.0 × 10−4 32 189 Chemokine signaling pathway
ADCY6, ADCY7, ADRBK2, ARRB2, CCL13, CCL18, CCL19, CCL2, 
CCL22, CCL3, CCL4, CCL5, CCR1, CXCL10, CXCL16, CXCR4, 
DOCK2, FGR, GNAI1, GNB4, GNG2, GRB2, HCK, PIK3R5, PREX1, 
PRKCB, PRKX, RAC2, STAT2, STAT3, TIAM1, VAV1
7.4 × 10−4 21 117 Leukocyte transendothelial migration
ACTB, ACTG1, ACTN1, CXCR4, CYBA, EZR, F11R, GNAI1, ICAM1, 
ITGAL, ITGB2, MMP9, MSN, MYL9, NCF2, NCF4, PIK3R5, PRKCB, 
RAC2, THY1, VAV1
2.5 × 10−3 16 95 Fc gamma R-mediated phagocytosis ARF6, CFL2, DOCK2, FCGR2A, FCGR2B, FCGR3A, HCK, LAT, PIK3R5, PPAP2B, PRKCB, PTPRC, RAC2, SCIN, SYK, VAV1
1.9 × 10−3 17 102 Toll-like receptor signaling pathway CCL3, CCL4, CCL5, CD14, CD86, CXCL10, IRAK1, LBP, LY96, MAP2K3, MAPK10, PIK3R5, SPP1, TLR1, TLR5, TLR7, TLR8
2.8 × 10−3 10 65 Glycolysis/Gluconeogenesis ADH1B, ALDH2, ALDH3B1, ALDH7A1, ENO1, GALM, HK3, PDHB, PFKP, PGAM2
7.8.0 × 10−3 5 17 Renin-angiotensin system AGTR1, ANPEP, CTSA, CTSG, NLN
3.3 × 10−3 6 17 Other glycan degradation FUCA1, FUCA2, GBA, GLB1, HEXB, MAN2B1
1.3 × 10−2 12 75 B cell receptor signaling pathway BLNK, DAPP1, FCGR2B, GRB2, NFKBIE, PIK3AP1, PIK3R5, PRKCB, PTPN6, RAC2, SYK, VAV1
1.3 × 10−2 5 19 Glycosaminoglycan degradation ARSB, GLB1, GUSB, HEXB, HPSE
1.1 × 10−2 9 48 Amino sugar and nucleotide sugar metabolism CHI3L1, CHIT1, GNE, GNPDA1, HEXB, HK3, NAGK, NPL, PMM1
1.7 × 10−2 11 69 Complement and coagulation cascades C1QA, C1QB, C1QC, C1R, C1S, C3AR1, C5AR1, F13A1, PLAU, PLAUR, SERPINE1
3.5 × 10−2 17 136 Natural killer cell mediated cytotoxicity BID, CD48, FCER1G, FCGR3A, GRB2, HCST, ICAM1, ITGAL, ITGB2, LAT, PIK3R5, PRKCB, PTPN6, RAC2, SYK, TYROBP, VAV1
1.2 × 10−2 25 200 Focal adhesion
ACTB, ACTG1, ACTN1, BIRC3, CCND2, COL6A1, COL6A2, COL6A6, 
FLNA, GRB2, ITGB5, LAMB3, MAPK10, MYL9, PDGFA, PIK3R5, 
PPP1CA, PRKCB, PTEN, RAC2, SPP1, TNC, VAV1, VEGFA, ZYX
Table 3.  Up-regulated pathways in the adipose tissue of high HOMA-IR group. Count = Amount of 
differentially expressed genes that map in pathway. Size = Total amount of genes involved in pathway.
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with earlier reports, which have suggested that these amino acids may stimulate insulin secretion from the pan-
creas21,28,29. On the other hand, elevated insulin may increase circulating BCAA, possibly by attenuating BCAA 
catabolism in different tissues as suggested by Sunny et al.24. Indeed, obesity-related increases in circulating 
BCAAs have been associated with decreased BCAA catabolism in adipose tissue30. Here, we showed significant 
down-regulation of the BCAA degradation pathway genes in the adipose tissue of normoglycemic subjects with 
high insulin resistance. The fact that there was no difference in average BMI or percent body fat between the low 
and high HOMA-IR groups suggests that down-regulation of the BCAA catabolism pathway was not attributable 
to adiposity alone. Thus, the decrease in the BCAA catabolism can probably be ascribed to reduced mitochon-
drial respiration and biogenesis (as indicated by the close correlation of the BCAA catabolism with the TCA cycle 
and PPARGC1A genes). Since physical activity and aerobic fitness are known to improve insulin sensitivity and 
energy metabolism31, it is possible that differences in physical activity and aerobic fitness may have amplified 
the observed differences in gene expression between the low and high HOMA-IR groups. The close correlation 
between VO2max and BCAA catabolism and the TCA cycle further support this notion.
Growing evidence indicates that obesity-associated low-grade inflammation of adipose tissue contributes 
to the development of insulin resistance32. Our results complement this notion by showing that up-regulated 
inflammation-related genes were closely associated with insulin resistance, serum adiponectin and leptin also 
in normoglycemic individuals, even after adjusting for measures of adiposity. Earlier studies have demonstrated 
that plasma adiponectin and leptin levels are associated with insulin resistance independent of fat mass33–35, and 
they may play a key role in the regulation of inflammation and immunity36. In line with earlier studies37,38, we 
found that the innate inflammatory component related to macrophages was coordinately up-regulated with insu-
lin resistance. The physiological role of macrophages is probably to clear adipose debris through the process of 
phagocytosis and activate the adaptive immune system39. Accordingly, we found that in terms of over-expressed 
genes the most up-regulated pathways in the adipose tissue were lysosome and phagosome pathways. These 
findings, (together with activation and infiltration of lymphocytes, a toll-like receptor signaling pathway, and the 
complement system) suggest a state of chronic low-grade inflammation in the adipose tissue. Furthermore, the 
chronic inflammation may also in part explain the observed impairments in adipose tissue energy metabolism 
(as indicated by the close inverse correlation of chemokine signaling genes with BCAA catabolism and the TCA 
cycle genes).
Impaired insulin-mediated skeletal muscle glucose uptake40 and intramyocellular lipid concentrations41 are 
major contributors to insulin resistance and type 2 diabetes. In our study, intramuscular triglycerides were not 
increased in subjects with high HOMA-IR. Consistent with this, no aberrant gene expression in individuals with 
high HOMA-IR was found. To confirm these findings, we further studied whether there were differences in the 
phosphorylation levels of several signaling proteins related to glucose metabolism. No significant differences in 
the phosphorylation levels of insulin receptor β and its downstream target Akt, were found, nor was there any 
significant difference in the level of phosphorylated AS160, which promotes translocation of glucose transporters 
to the cell membrane. Previous studies have reported reduced muscle transcript levels related to oxidative metab-
olism in diabetic individuals compared to healthy controls42. We found no difference in mitochondrial respiratory 
chain complex subunits between the low and high HOMA-IR groups. These findings suggest that in the fasting 
state glucose and mitochondrial energy metabolism is not significantly altered in the skeletal muscle in early 
stages of insulin resistance. However, since both acute hyperinsulinemia43 and hyperglycemia44 have been shown 
to induce transcriptional and translational regulation of glucose and energy metabolism in the skeletal muscle, it 
may be that significant differences could exist during hyperinsulinemic-euglycemic clamp, glucose challenge or 
mixed meal feeding.
This study has some limitations. First, the number of participants in our study was relatively small and 
consisted solely of women. Despite this we were able to identify statistically significant differences in serum 
P-value Count Size Pathway name Genes
1.1 × 10−7 17 44 Valine, leucine and isoleucine catabolism
ACADM, ACADSB, ALDH2, ALDH6A1, ALDH7A1, AUH, 
BCAT1, BCKDHB, DLD, HADH, HIBADH, IL4I1, MCCC2, MUT, 
OXCT1, PCCA, PCCB
3.7 × 10−4 10 32 Proprionate metabolism ACACB, ACADM, ACSS3, ALDH2, ALDH6A1, ALDH7A1, MUT, PCCA, PCCB, SUCLG2
2.9 × 10−3 6 17 Phenylalanine metabolism ALDH3B1, AOC2, IL4I1, MAOB, MIF, PRDX6
4.4 × 10−3 10 43 Fatty acid degradation ACADL, ACADM, ACADSB, ADH1B, ADH1C, ALDH2, ALDH7A1, CPT1A, HADH, PECI
1.2 × 10−2 9 42 Tryptophan metabolism ALDH2, ALDH7A1, CAT, CYP1B1, HADH, IL4I1, KMO, KYNU, MAOB
1.6 × 10−2 7 30 Citrate cycle (TCA cycle) DLD, DLST, IDH3B, PC, PDHB, SDHB, SUCLG2
2.9 × 10−2 8 41 Tyrosine metabolism ADH1B, ADH1C, ALDH3B1, AOC2, COMT, IL4I1, MAOB, MIF
1.7 × 10−2 2 3 Lysine biosynthesis AASS, ALDH7A1
4.7 × 10−2 4 18 Glyoxylate and dicarboxylate metabolism HYI, MUT, PCCA, PCCB
1.9 × 10−2 12 68 Adipocytokine signaling pathway ACACB, ADIPOQ, ADIPOR1, CPT1A, MAPK10, NFKBIE, PPARA, PPARGC1A, PRKAG1, SLC2A4, STAT3, TNFRSF1B
Table 4.  Down-regulated pathways in the adipose tissue of high HOMA-IR group. Count = Amount of 
differentially expressed genes that map in pathway. Size = Total amount of genes involved in pathway.
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metabolites and gene expressions in adipose tissue between the groups. In addition, the participants were care-
fully selected in order to minimize confounding factors and genetic variability. Furthermore, gene expression 
in the adipose tissue of participants with high HOMA-IR was validated by two independent experiments with 
non-obese type 2 diabetic and obese insulin-resistant subjects. Thus, we believe that our results are not biased and 
that the gene expression data can be viewed with confidence. Finally, the majority of the participants were within 
the normal fasting glycemic range and exclusion of those with impaired fasting glucose did not change the results. 
This gave us the possibility to identify the biomarkers associated with systemic insulin resistance in its early stage.
Our data demonstrate that serum fatty acids, intra-myocellular lipids and liver fat content were not elevated 
in normoglycemic women with high HOMA-IR. Instead, we show that impaired insulin sensitivity was associ-
ated with a significant increase in serum BCAA concentration, up-regulation of inflammation-related genes and 
down-regulation of genes related to BCAA catabolism and mitochondrial energy metabolism in adipose tissue. 
These findings suggest that adipose tissue inflammation and mitochondrial dysfunction may be early events in 
the development of systemic insulin resistance. Further studies are needed to determine the initial factor(s) that 
trigger the transcriptional changes that lead to these metabolic alterations.
Figure 1. Up-regulated inflammation-related genes in the adipose tissue in insulin resistant compared 
to insulin sensitive group. The y-axis shows the fold change of gene expression of up-regulated genes in high 
HOMA-IR subjects of the present study (A) and obese insulin resistant subjects in the study of Soronen et al. 
(B)15 and Hardy et al.16 (C).
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Materials and Methods
Study subjects. This article is part of a large family study with 282 participating families and has been 
described elsewhere45. A subgroup of families (n = 74), comprising 222 individuals (daughter, mother and father) 
with no type I/II diabetes or family history (first degree relative) of diabetes, cardiac diseases, autoimmune dis-
eases or major liver (cancer, hepatitis) diseases were contacted by letter for an additional study aimed at identify-
ing biomarkers associated with insulin resistance and liver fat accumulation. A total of 184 individuals responded 
to our invitation, of whom 163 (53 fathers, 53 mothers and 57 daughters) attended the laboratory tests. For this 
report, all the fathers were excluded in order to reduce the variability in genetic architecture, leaving only the 
mothers and daughters (mothers = 53 and daughters = 57). Mothers and daughters did not differ in measures 
of adiposity, insulin resistance, serum triglycerides, fatty acids or amino acids. Therefore, all data including the 
metabolome and microarray data were pooled before the phenotypic analysis and all results were adjusted for 
age and familiarity. Further, to minimize the metabolic alterations occurring at different stages of the menstrual 
cycle, blood samples were collected from the women with regular menses between 2 and 5 days after (menstru-
ation). Twenty-two participants were in early post menopause but none were on hormonal replacement therapy. 
Including or excluding these participants did not influence the results. All subjects were clinically euthyreotic. 
The study protocol was approved by the ethics committee of the Central Finland Health Care District. A written 
informed consent was obtained from all participants, and all experiments were performed in accordance with 
relevant guidelines and regulations.
Methods. A detailed description of the background information and methods are provided in supplemen-
tary text S1. In short, background information including medical history, current health status and physical 
activity was collected via self-administered questionnaires. Food consumption and intakes of total energy and 
energy-yielding nutrients were assessed from three-day food records. All measurements were performed in 
the morning after overnight fasting. Venous blood samples were obtained for the analyses of glucose, insulin, 
Figure 2. Correlations between the mean centroids of the BCAA catabolism pathway and fs-insulin and 
insulin sensitivity (Matsuda index). The values of fs-insulin and the Matsuda index were transformed to 
normal distribution by natural logarithms. Each dot represents an individual and the line is a linear regression 
fit line.
Figure 3. Correlation between the mean centroids of the BCAA catabolism pathway and the TCA cycle and 
PPARGC1A. Each dot represents an individual and the line is a linear regression fit line.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:24540 | DOI: 10.1038/srep24540
non-esterified fatty acids, leptin, and adiponectin. The HOMA-IR index (homeostatic model assessment of 
insulin resistance) was calculated as (fasting glucose x fasting insulin/22.5). According their HOMA-IR values 
(median = 1.57), the subjects were divided into low (n = 55) and high (n = 55) groups. Body composition was 
assessed by DXA, subcutaneous and intra-abdominal adipose tissue by MRI46, and ectopic fat of liver, mus-
cle intra-myocellular lipid (IMCL) and extra-myocellular lipid (EMCL) by 1HMRS47. Serum metabolites were 
assessed by NMR spectroscopy48. Maximum oxygen uptake (VO2max, ml/kg/min) was assessed by a bicycle ergom-
eter test. In addition, superficial abdominal subcutaneous adipose tissue and skeletal muscle (vastus lateralis) 
biopsies were obtained from 24 individuals to assess the differences in global gene expression profiles and muscle 
protein expression between the low and high HOMA-IR groups. Furthermore, a 75-g oral glucose tolerance test 
(OGTT) was performed for subjects with tissue biopsies to assess whole body insulin sensitivity49. Microarray 
measurements were analyzed by using the Robust Multiarray Averaging (RMA) algorithm in the Bioconductor 
R package affy50–52. The Limma R package was used for differentially expressed genes (DEGs). Raw p values were 
adjusted to control for the false discovery rate (FDR) using the method of Benjamini and Hochberg53 (for more 
detailed information on microarray and gene enrichment analysis see supplementary text S1).
Statistical methods. Before each analysis, continuous data were checked for normality by Shapiro-Wilk’s 
test using PASW statistics version 21 (IBM Corporation, USA). If data were not normally distributed, their 
natural logarithms were used. Clinical characteristics and serum metabolites were compared using an 
independent-samples t-test. Since the data were from a family study, the familiarity (genetic and environmental 
(household) similarity) was controlled by using linear mixed model to compare levels of the outcome variables 
between the low and high HOMA-IR groups. Contrast tests were used in mixed models to assess the effect of 
generation while controlling for dependency among family members with random effects. P-values were adjusted 
to control for the false discovery rate (FDR) using the method of Benjamini and Hochberg when comparing 
metabolites between the low and high HOMA-IR groups53. Pearson correlation analysis was used to determine 
the relationship between clinical characteristics, serum metabolites and adipose tissue gene expression. Statistical 
significance was set at p < 0.05.
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